Research Reports | Market Assessment
December 2015

Hospital-Treated Infections | Physician & Payer Forum | Brazil/Mexico | 2015

The prevalence of difficult-to-treat infections is increasing worldwide, despite regional variations in the etiological pathogens. This report provides an extensive overview of the use of antibiotics in Brazil and Mexico, with a special focus on complicated hospital-treated infections (HTIs) due to methicillin-resistant Staphylococcus aureus (MRSA) and gram-negative pathogens. Such multi-drug resistant pathogens are becoming increasingly life-threatening and burdensome to local healthcare economies, which are overflowing with generics from a broad range of antibiotic classes. However, governments are keen to regulate the use of antibiotics so that forthcoming multi-drug resistance can be restrained. Healthcare providers struggle to employ more effective and costly antibiotics that address complicated infections caused by resistant pathogens in these cost-constrained markets. Thus, novel antibiotics, such as Actavis/AstraZeneca’s Avycaz, The Medicines Company’s Carbavance, Tetraphase’s eravacycline, and Merck’s Zerbaxa, must overcome stringent clinical and reimbursement challenges.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports